HLB bioStepLtd Past Earnings Performance
Past criteria checks 0/6
HLB bioStepLtd's earnings have been declining at an average annual rate of -27.9%, while the Life Sciences industry saw earnings growing at 21.5% annually. Revenues have been growing at an average rate of 11.2% per year.
Key information
-27.9%
Earnings growth rate
-28.8%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 11.2% |
| Return on equity | -0.05% |
| Net Margin | -0.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%
Mar 29
Here's Why HLB bioStepLtd (KOSDAQ:278650) Has A Meaningful Debt Burden
Feb 28With EPS Growth And More, KNOTUSLtd (KOSDAQ:278650) Is Interesting
Mar 17What Kind Of Investors Own Most Of KNOTUS Co.,Ltd (KOSDAQ:278650)?
Feb 24Is KNOTUSLtd (KOSDAQ:278650) Using Too Much Debt?
Feb 03
Investors Who Bought KNOTUSLtd (KOSDAQ:278650) Shares A Year Ago Are Now Up 26%
Jan 13Should We Be Delighted With KNOTUS Co.,Ltd's (KOSDAQ:278650) ROE Of 15%?
Dec 23Is Now The Time To Put KNOTUSLtd (KOSDAQ:278650) On Your Watchlist?
Dec 02Revenue & Expenses BreakdownBeta
How HLB bioStepLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 52,814 | -164 | 32,209 | 812 |
| 30 Sep 23 | 62,832 | -3,356 | 34,891 | 342 |
| 30 Jun 23 | 74,209 | -2,883 | 37,627 | 659 |
| 31 Mar 23 | 82,152 | -3,422 | 40,487 | 929 |
| 31 Dec 22 | 86,277 | -1,008 | 42,834 | 978 |
| 30 Sep 22 | 81,360 | 4,934 | 39,002 | 1,548 |
| 30 Jun 22 | 74,421 | 7,590 | 42,414 | 1,096 |
| 31 Mar 22 | 67,695 | 9,911 | 37,129 | 1,020 |
| 31 Dec 21 | 64,403 | 11,031 | 27,362 | 1,165 |
| 30 Sep 21 | 61,934 | 8,423 | 29,051 | 713 |
| 30 Jun 21 | 58,661 | 8,511 | 25,759 | 713 |
| 31 Mar 21 | 58,528 | 8,463 | 28,050 | 844 |
| 31 Dec 20 | 58,520 | 8,302 | 32,020 | 1,085 |
| 30 Sep 20 | 55,269 | 7,338 | 28,968 | 1,724 |
| 30 Jun 20 | 54,902 | 6,322 | 29,053 | 1,724 |
| 31 Mar 20 | 49,776 | 5,302 | 24,525 | 1,322 |
| 31 Dec 19 | 46,040 | 4,195 | 24,488 | 1,012 |
| 30 Sep 19 | 42,821 | 3,495 | 25,879 | 342 |
| 31 Mar 19 | 40,390 | 3,816 | 24,423 | 655 |
Quality Earnings: A278650 is currently unprofitable.
Growing Profit Margin: A278650 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A278650 is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.
Accelerating Growth: Unable to compare A278650's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A278650 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (8.1%).
Return on Equity
High ROE: A278650 has a negative Return on Equity (-0.052%), as it is currently unprofitable.